Form 4: Kiniksa Pharmaceuticals International, plc: Officer Tessari Eben Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Kiniksa Pharmaceuticals' Chief Operating Officer, Tessari Eben, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- On September 23, 2024, Tessari Eben, the Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, exercised options to acquire 10,000 Class A Ordinary Shares at a price of $1.59 per share.
- On the same day, Tessari Eben sold 17,500 Class A Ordinary Shares at a weighted average price of $24.99 per share, with prices ranging from $24.62 to $25.60.
- These transactions were executed under a pre-existing 10b5-1 trading plan established on April 29, 2024.
- Following these transactions, Tessari Eben directly owns 116,975 Class A Ordinary Shares and 36,017 Share Options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports transactions. The use of a 10b5-1 plan suggests pre-planned transactions, reducing potential negative interpretations.
Future Outlook
There is no future outlook provided in this document.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The use of a 10b5-1 plan suggests that the transactions were pre-planned and not based on any material non-public information.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly listed companies, and the reporting requirements are standardized by the SEC.
- The use of 10b5-1 plans is a widely accepted practice to allow insiders to sell shares without being accused of trading on non-public information.
- Comparable companies such as Amgen, Regeneron, and Biogen also have executives who regularly trade company stock under similar plans.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the potential dilution from option exercises and the selling pressure from the share sales.
- However, the use of a 10b5-1 plan mitigates concerns about insider trading and ensures transparency.
Key Dates
| Date | Description |
|---|---|
| 04/29/2024 | Date of execution of the 10b5-1 plan by the reporting person |
| 09/23/2024 | Date of the transaction: exercise of stock options and sale of shares |
| 09/25/2024 | Date of signature of the Form 4 filing |
| 12/15/2025 | Expiration date of the share option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.